clinic data updat pt
messag report full-year result in-lin
expect compani remain on-track read preclin combin data
select inhibitor repotrectinib well next-gen inhibitor
ind submiss expect earli clinic updat includ initi interim data
pivot studi evalu repotrectinib lung cancer ntrk solid
tumor patient initi data inhibitor remain on-track
buy rate pt see initi preview
recal next-gener research engin focus macrocycl tki
overcom mechan treatment resist current inhibitor lead product
repotrectinib trk inhibitor demonstr earli highli promis data
highlight potenti best-in-class characterist rel competitor xalkori
rozlytrek rog-sw link non-smal cell lung cancer nsclc opportun
consist nsclc compani platform also gener current early-
stage asset includ inhibitor ret inhibitor inhibitor
see also recent oncolog day panel select tki nsclc
compani remain on-track head preclin clinic data
readout key pipelin asset addit monotherapi compani explor
potenti combin regimen repotrectinib expect read preclin
combin data lieu present postpon
confer preclin data next-gener inhibitor read
similar manner compani still expect read initi interim data registration-
enabl trial initi clinic data inhibitor
updat estim account result modestli adjust
oper expens forecast finish quarter expect
page analyst certif import disclosur
valu per share use dcf analysi use wacc consist clinical-
stage biotech compani cover proof-of-concept data well termin growth rate risk includ regulatori
commerci setback potenti emerg new competitor lower product sale expect dilut financ beyond
assum
page analyst certif import disclosur
total cost expens
interest incom net
loss extinguish debt
incom tax
guggenheim secur llc sec file
page analyst certif import disclosur
